Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism

Larry Scahill, Nilda Gonzalez, Kathleen Koenig, Ronald Lindsay, Andres Martin, James McGough, David J. Posey, Naomi Swiezy, Fred Volkmar, Louise Ritz, Benedetto Vitiello, James McCracken, Christopher J. McDougle, Michael Aman, L. Eugene Arnold, Naomi Swiezy, Pegeen Cronin, Mark Davies, Jaswinder Ghuman

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: To describe the methodological challenges and decisions made in developing a multisite, controlled study of risperidone in children and adolescents with autism. Methods: Review the design considerations for clinical trials in children with autistic disorder accompanied by severe tantrums, aggressive and/or self-injurious behaviors. These design considerations include the definition of inclusion criteria that are relevant to clinical practice and matching study design to the goal of evaluating short- and long-term effects. Additional ethical and scientific issues concern the length of trial and sample size. Results: We undertook a short-term, placebo-controlled study to evaluate the efficacy and safety of risperidone in children and adolescents with autistic disorder. This trial design was followed by an extended open-label maintenance on risperidone to confirm durability of treatment effects and to monitor safety. Finally, a placebo-controlled discontinuation study tested the need for continuous treatment. Conclusions: In the absence of standard pharmacological treatment for children with autistic disorder, a placebo-controlled study remains the most appropriate method of testing efficacy and safety. The clinical relevance of this study is enhanced by the addition of an extended maintenance phase followed by a placebo discontinuation.

Original languageEnglish (US)
Pages (from-to)377-388
Number of pages12
JournalJournal of Child and Adolescent Psychopharmacology
Volume11
Issue number4
StatePublished - 2001

Fingerprint

Risperidone
Autistic Disorder
Placebos
Safety
Maintenance
Self-Injurious Behavior
Ethics
Sample Size
Therapeutics
Clinical Trials
Pharmacology

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Scahill, L., Gonzalez, N., Koenig, K., Lindsay, R., Martin, A., McGough, J., ... Ghuman, J. (2001). Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. Journal of Child and Adolescent Psychopharmacology, 11(4), 377-388.

Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. / Scahill, Larry; Gonzalez, Nilda; Koenig, Kathleen; Lindsay, Ronald; Martin, Andres; McGough, James; Posey, David J.; Swiezy, Naomi; Volkmar, Fred; Ritz, Louise; Vitiello, Benedetto; McCracken, James; McDougle, Christopher J.; Aman, Michael; Arnold, L. Eugene; Swiezy, Naomi; Cronin, Pegeen; Davies, Mark; Ghuman, Jaswinder.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 11, No. 4, 2001, p. 377-388.

Research output: Contribution to journalArticle

Scahill, L, Gonzalez, N, Koenig, K, Lindsay, R, Martin, A, McGough, J, Posey, DJ, Swiezy, N, Volkmar, F, Ritz, L, Vitiello, B, McCracken, J, McDougle, CJ, Aman, M, Arnold, LE, Swiezy, N, Cronin, P, Davies, M & Ghuman, J 2001, 'Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism', Journal of Child and Adolescent Psychopharmacology, vol. 11, no. 4, pp. 377-388.
Scahill, Larry ; Gonzalez, Nilda ; Koenig, Kathleen ; Lindsay, Ronald ; Martin, Andres ; McGough, James ; Posey, David J. ; Swiezy, Naomi ; Volkmar, Fred ; Ritz, Louise ; Vitiello, Benedetto ; McCracken, James ; McDougle, Christopher J. ; Aman, Michael ; Arnold, L. Eugene ; Swiezy, Naomi ; Cronin, Pegeen ; Davies, Mark ; Ghuman, Jaswinder. / Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. In: Journal of Child and Adolescent Psychopharmacology. 2001 ; Vol. 11, No. 4. pp. 377-388.
@article{d8a12081d84c4abdbaeb0991730d9d40,
title = "Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism",
abstract = "Objective: To describe the methodological challenges and decisions made in developing a multisite, controlled study of risperidone in children and adolescents with autism. Methods: Review the design considerations for clinical trials in children with autistic disorder accompanied by severe tantrums, aggressive and/or self-injurious behaviors. These design considerations include the definition of inclusion criteria that are relevant to clinical practice and matching study design to the goal of evaluating short- and long-term effects. Additional ethical and scientific issues concern the length of trial and sample size. Results: We undertook a short-term, placebo-controlled study to evaluate the efficacy and safety of risperidone in children and adolescents with autistic disorder. This trial design was followed by an extended open-label maintenance on risperidone to confirm durability of treatment effects and to monitor safety. Finally, a placebo-controlled discontinuation study tested the need for continuous treatment. Conclusions: In the absence of standard pharmacological treatment for children with autistic disorder, a placebo-controlled study remains the most appropriate method of testing efficacy and safety. The clinical relevance of this study is enhanced by the addition of an extended maintenance phase followed by a placebo discontinuation.",
author = "Larry Scahill and Nilda Gonzalez and Kathleen Koenig and Ronald Lindsay and Andres Martin and James McGough and Posey, {David J.} and Naomi Swiezy and Fred Volkmar and Louise Ritz and Benedetto Vitiello and James McCracken and McDougle, {Christopher J.} and Michael Aman and Arnold, {L. Eugene} and Naomi Swiezy and Pegeen Cronin and Mark Davies and Jaswinder Ghuman",
year = "2001",
language = "English (US)",
volume = "11",
pages = "377--388",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism

AU - Scahill, Larry

AU - Gonzalez, Nilda

AU - Koenig, Kathleen

AU - Lindsay, Ronald

AU - Martin, Andres

AU - McGough, James

AU - Posey, David J.

AU - Swiezy, Naomi

AU - Volkmar, Fred

AU - Ritz, Louise

AU - Vitiello, Benedetto

AU - McCracken, James

AU - McDougle, Christopher J.

AU - Aman, Michael

AU - Arnold, L. Eugene

AU - Swiezy, Naomi

AU - Cronin, Pegeen

AU - Davies, Mark

AU - Ghuman, Jaswinder

PY - 2001

Y1 - 2001

N2 - Objective: To describe the methodological challenges and decisions made in developing a multisite, controlled study of risperidone in children and adolescents with autism. Methods: Review the design considerations for clinical trials in children with autistic disorder accompanied by severe tantrums, aggressive and/or self-injurious behaviors. These design considerations include the definition of inclusion criteria that are relevant to clinical practice and matching study design to the goal of evaluating short- and long-term effects. Additional ethical and scientific issues concern the length of trial and sample size. Results: We undertook a short-term, placebo-controlled study to evaluate the efficacy and safety of risperidone in children and adolescents with autistic disorder. This trial design was followed by an extended open-label maintenance on risperidone to confirm durability of treatment effects and to monitor safety. Finally, a placebo-controlled discontinuation study tested the need for continuous treatment. Conclusions: In the absence of standard pharmacological treatment for children with autistic disorder, a placebo-controlled study remains the most appropriate method of testing efficacy and safety. The clinical relevance of this study is enhanced by the addition of an extended maintenance phase followed by a placebo discontinuation.

AB - Objective: To describe the methodological challenges and decisions made in developing a multisite, controlled study of risperidone in children and adolescents with autism. Methods: Review the design considerations for clinical trials in children with autistic disorder accompanied by severe tantrums, aggressive and/or self-injurious behaviors. These design considerations include the definition of inclusion criteria that are relevant to clinical practice and matching study design to the goal of evaluating short- and long-term effects. Additional ethical and scientific issues concern the length of trial and sample size. Results: We undertook a short-term, placebo-controlled study to evaluate the efficacy and safety of risperidone in children and adolescents with autistic disorder. This trial design was followed by an extended open-label maintenance on risperidone to confirm durability of treatment effects and to monitor safety. Finally, a placebo-controlled discontinuation study tested the need for continuous treatment. Conclusions: In the absence of standard pharmacological treatment for children with autistic disorder, a placebo-controlled study remains the most appropriate method of testing efficacy and safety. The clinical relevance of this study is enhanced by the addition of an extended maintenance phase followed by a placebo discontinuation.

UR - http://www.scopus.com/inward/record.url?scp=0035706309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035706309&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 377

EP - 388

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 4

ER -